Published 2021
| Version v1
Publication
Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes
Creators
- Battistoni, Ilaria
- Francioni, Matteo
- Morici, Nuccia
- Rubboli, Andrea
- Podda, Gian Marco
- Pappalardo, Andrea
- Abdelrahim, Mohamed E A
- El Gendy, Osama S
- Khalaf, Ahmed M
- Hamied, Ahmed Abdel M
- Garcés, Héctor Hernández
- Abdelhamid, Omar E S
- Tawfik, Karim A M
- Zeduri, Anna
- Bassi, Gabriele
- Pongetti, Giulia
- Angelini, Luca
- Giovinazzo, Stefano
- Garcia, Pablo Martinez
- Serino, Francesco Saverio
- Polistina, Giorgio Emanuele
- Fiorentino, Giuseppe
- Barbati, Giovanni
- Toniolo, Anna
- Fabbrizioli, Azzurra
- Belenguer-Muncharaz, Alberto
- Porto, Italo
- Ocak, Sibel
- Minuz, Pietro
- Bernal, Francisco
- Hermosilla, Irina
- Borovac, Josip A
Contributors
Others:
- Battistoni, Ilaria
- Francioni, Matteo
- Morici, Nuccia
- Rubboli, Andrea
- Podda, Gian Marco
- Pappalardo, Andrea
- Abdelrahim, Mohamed E A
- El Gendy, Osama S
- Khalaf, Ahmed M
- Hamied, Ahmed Abdel M
- Garcés, Héctor Hernández
- Abdelhamid, Omar E S
- Tawfik, Karim A M
- Zeduri, Anna
- Bassi, Gabriele
- Pongetti, Giulia
- Angelini, Luca
- Giovinazzo, Stefano
- Garcia, Pablo Martinez
- Serino, Francesco Saverio
- Polistina, Giorgio Emanuele
- Fiorentino, Giuseppe
- Barbati, Giovanni
- Toniolo, Anna
- Fabbrizioli, Azzurra
- Belenguer-Muncharaz, Alberto
- Porto, Italo
- Ocak, Sibel
- Minuz, Pietro
- Bernal, Francisco
- Hermosilla, Irina
- Borovac, Josip A
Description
Aims: To estimate if chronic anticoagulant (CAC) treatment is associated with morbidity and mortality outcomes of patients hospitalized for SARS-CoV-2 infection. Methods: In this European multicentric cohort study, we included 1186 patients of whom 144 were on CAC (12.1%) with positive coronavirus disease 2019 testing between 1 February and 30 July 2020. The average treatment effect (ATE) analysis with a propensity score-matching (PSM) algorithm was used to estimate the impact of CAC on the primary outcomes defined as in-hospital death, major and minor bleeding events, cardiovascular complications (CCI), and acute kidney injury (AKI). We also investigated if different dosages of in-hospital heparin were associated with in-hospital survival. Results: In unadjusted populations, primary outcomes were significantly higher among CAC patients compared with non-CAC patients: all-cause death (35% vs. 18% P < 0.001), major and minor bleeding (14% vs. 8% P = 0.026; 25% vs. 17% P = 0.014), CCI (27% vs. 14% P < 0.001), and AKI (42% vs. 19% P < 0.001). In ATE analysis with PSM, there was no significant association between CAC and primary outcomes except for an increased incidence of AKI (ATE +10.2%, 95% confidence interval 0.3-20.1%, P = 0.044). Conversely, in-hospital heparin, regardless of dose, was associated with a significantly higher survival compared with no anticoagulation. Conclusions: The use of CAC was not associated with the primary outcomes except for the increase in AKI. However, in the adjusted survival analysis, any dose of in-hospital anticoagulation was associated with significantly higher survival compared with no anticoagulation.
Additional details
Identifiers
- URL
- http://hdl.handle.net/11567/1066375
- URN
- urn:oai:iris.unige.it:11567/1066375
Origin repository
- Origin repository
- UNIGE